Literature DB >> 21293864

Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced MRI to Dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis.

Rita Golfieri1, Matteo Renzulli, Vincenzo Lucidi, Beniamino Corcioni, Franco Trevisani, Luigi Bolondi.   

Abstract

OBJECTIVE: To prospectively assess the additional value of the hepatobiliary (HB) phase of Gd-EOB-DTPA-MRI in identifying and characterising small (≤ 2 cm) hepatocellular carcinomas (HCCs) undetermined in dynamic phases alone because of their atypical features, according to the AASLD criteria.
METHODS: 127 cirrhotic patients were evaluated with Gd-EOB-DTPA-MRI in two sets: unenhanced and dynamic phases; unenhanced, dynamic and HB phases. Sixty-two out of 215 nodules (29%) were atypical in 42 patients (33%).
RESULTS: 62 atypical nodules were reported at histology: high-grade dysplastic nodules (HGDN)/early HCC (n = 20), low-grade DN (LGDN) (n = 21), regenerative nodules (n = 17) and nodular regenerative hyperplasia (n = 4). The sensitivity, specificity, accuracy, positive and negative predictive value (PPV, NPV) were increased by the addition of the HB phase: 88.4-99.4%, 88-95%, 88-98.5%, 97-99%, and 65-97.5%, respectively. Twenty atypical nodules were malignant (32%), 19 of which were characterised only during the HB phase.
CONCLUSIONS: The HB phase is 11% more sensitive in the classification of HGDN/early HCC than dynamic MRI, with an added value of 32.5% in the NPV. The high incidence (33%) of atypical nodules and their frequent malignancy (32%) suggest the widespread employment of Gd-EOB-DTPA-MRI in the follow-up of small nodules (≤ 2 cm) in cirrhosis.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21293864     DOI: 10.1007/s00330-010-2030-1

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  56 in total

1.  Large regenerative nodules in Budd-Chiari syndrome and other vascular disorders of the liver: CT and MR imaging findings with clinicopathologic correlation.

Authors:  Giuseppe Brancatelli; Michael P Federle; Luigi Grazioli; Rita Golfieri; Riccardo Lencioni
Journal:  AJR Am J Roentgenol       Date:  2002-04       Impact factor: 3.959

2.  Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.

Authors:  A Spinazzi; V Lorusso; G Pirovano; M Kirchin
Journal:  Acad Radiol       Date:  1999-05       Impact factor: 3.173

Review 3.  Focus on dysplastic nodules and early hepatocellular carcinoma: an Eastern point of view.

Authors:  Masamichi Kojiro
Journal:  Liver Transpl       Date:  2004-02       Impact factor: 5.799

4.  The STARD statement for reporting studies of diagnostic accuracy: explanation and elaboration.

Authors:  Patrick M Bossuyt; Johannes B Reitsma; David E Bruns; Constantine A Gatsonis; Paul P Glasziou; Les M Irwig; David Moher; Drummond Rennie; Henrica C W de Vet; Jeroen G Lijmer
Journal:  Ann Intern Med       Date:  2003-01-07       Impact factor: 25.391

5.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

6.  Gd-EOB-DTPA-enhanced magnetic resonance images of hepatocellular carcinoma: correlation with histological grading and portal blood flow.

Authors:  Sachiyo Kogita; Yasuharu Imai; Masahiro Okada; Tonsok Kim; Hiromitsu Onishi; Manabu Takamura; Kazuto Fukuda; Takumi Igura; Yoshiyuki Sawai; Osakuni Morimoto; Masatoshi Hori; Hiroaki Nagano; Kenichi Wakasa; Norio Hayashi; Takamichi Murakami
Journal:  Eur Radiol       Date:  2010-05-19       Impact factor: 5.315

7.  Added value of gadoxetic acid-enhanced hepatobiliary phase MR imaging in the diagnosis of hepatocellular carcinoma.

Authors:  Sung Soo Ahn; Myeong-Jin Kim; Joon Seok Lim; Hye-Suk Hong; Yong Eun Chung; Jin-Young Choi
Journal:  Radiology       Date:  2010-05       Impact factor: 11.105

8.  Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging--correlation with molecular transporters and histopathologic features.

Authors:  Azusa Kitao; Yoh Zen; Osamu Matsui; Toshifumi Gabata; Satoshi Kobayashi; Wataru Koda; Kazuto Kozaka; Norihide Yoneda; Tatsuya Yamashita; Shuichi Kaneko; Yasuni Nakanuma
Journal:  Radiology       Date:  2010-07-27       Impact factor: 11.105

Review 9.  Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy.

Authors:  Masatoshi Kudo
Journal:  Oncology       Date:  2008-12-17       Impact factor: 2.935

10.  Gadoxetic acid-enhanced MRI versus triple-phase MDCT for the preoperative detection of hepatocellular carcinoma.

Authors:  Seong Hyun Kim; Seung Hoon Kim; Jongmee Lee; Min Ju Kim; Yong Hwan Jeon; Yulri Park; Dongil Choi; Won Jae Lee; Hyo K Lim
Journal:  AJR Am J Roentgenol       Date:  2009-06       Impact factor: 3.959

View more
  63 in total

1.  Added value of hepatobiliary phase gadoxetic acid-enhanced MRI for diagnosing hepatocellular carcinoma in high-risk patients.

Authors:  Sith Phongkitkarun; Kuruwin Limsamutpetch; Penampai Tannaphai; Janjira Jatchavala
Journal:  World J Gastroenterol       Date:  2013-12-07       Impact factor: 5.742

Review 2.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

3.  Perfusion computed tomography for detection of hepatocellular carcinoma in patients with liver cirrhosis.

Authors:  Michael A Fischer; Nikolaos Kartalis; Aristeidis Grigoriadis; Louiza Loizou; Per Stål; Bertil Leidner; Peter Aspelin; Torkel B Brismar
Journal:  Eur Radiol       Date:  2015-04-23       Impact factor: 5.315

Review 4.  Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.

Authors:  Stefano Palmucci
Journal:  World J Hepatol       Date:  2014-07-27

5.  Hepatocellular carcinoma: clinical significance of signal heterogeneity in the hepatobiliary phase of gadoxetic acid-enhanced MR imaging.

Authors:  Nobuhiro Fujita; Akihiro Nishie; Yuichiro Kubo; Yoshiki Asayama; Yasuhiro Ushijima; Yukihisa Takayama; Koichiro Moirta; Ken Shirabe; Shinichi Aishima; Hiroshi Honda
Journal:  Eur Radiol       Date:  2014-07-26       Impact factor: 5.315

6.  The challenges of novel contrast agents for the imaging diagnosis of hepatocellular carcinoma.

Authors:  Carmen Ayuso; Jordi Bruix
Journal:  Hepatol Int       Date:  2013-12-28       Impact factor: 6.047

Review 7.  Magnetic resonance imaging of the cirrhotic liver: An update.

Authors:  Agnes Watanabe; Miguel Ramalho; Mamdoh AlObaidy; Hye Jin Kim; Fernanda G Velloni; Richard C Semelka
Journal:  World J Hepatol       Date:  2015-03-27

8.  Factors predicting aggressiveness of non-hypervascular hepatic nodules detected on hepatobiliary phase of gadolinium ethoxybenzyl diethylene-triamine-pentaacetic-acid magnetic resonance imaging.

Authors:  Tsutomu Kanefuji; Toru Takano; Takeshi Suda; Kouhei Akazawa; Takeshi Yokoo; Hiroteru Kamimura; Kenya Kamimura; Atsunori Tsuchiya; Masaaki Takamura; Hirokazu Kawai; Satoshi Yamagiwa; Hidefumi Aoyama; Minoru Nomoto; Shuji Terai
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

9.  Evolution of indeterminate hepatocellular nodules at Gd-EOB-DPTA-enhanced MRI in cirrhotic patients.

Authors:  Massimo Galia; Francesco Agnello; Gianvincenzo Sparacia; Domenica Matranga; Domenico Albano; Massimo Midiri; Roberto Lagalla
Journal:  Radiol Med       Date:  2018-03-15       Impact factor: 3.469

Review 10.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.